Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial

Nov 25, 2025Diabetes, obesity & metabolism

How starting factors relate to treatment results with tirzepatide in Japanese patients with obesity

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Weight reduction at week 72 was generally similar across subgroups, with 86%-100% of users achieving at least 5% weight loss.

Females experienced greater percent body weight reductions with tirzepatide compared to males.
Participants with a body mass index (BMI) below 35 kg/m had larger weight reductions than those with a BMI of 35 kg/m or more.
All subgroups showed improvements in cardiometabolic health markers with tirzepatide treatment.
Safety profiles of tirzepatide did not significantly vary between different demographic subgroups.

AI simplified

AIMS: This analysis aimed to assess the influence of selected baseline factors on treatment response in Japanese patients with .

MATERIALS AND METHODS: This was a prespecified subgroup analysis of the SURMOUNT-J trial. Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo. Key safety and efficacy outcomes at week 72 were analysed by baseline characteristics, including sex, age (<65, ≥65 years), and body mass index (BMI; <35 kg/m, ≥35 kg/m). Post hoc analyses were conducted to examine cardiometabolic parameters by subgroup. 2 2

RESULTS: Overall, 225 participants were examined (tirzepatide 10 mg: n = 73; tirzepatide 15 mg: n = 77; placebo: n = 75). Weight reduction at week 72 was generally similar across subgroups. Numerically greater reductions in percent body weight at week 72 were observed in females (estimated treatment differences: 10 mg, -17.5%; 15 mg, -24.9%) compared with males (10 mg, -15.1%; 15 mg, -18.1%) and in the BMI <35 kg/msubgroup (10 mg, -18.7%; 15 mg, -21.7%) compared with the BMI ≥35 kg/msubgroup (10 mg, -11.7%; 15 mg, -20.4%) with tirzepatide compared with placebo. Higher proportions of participants achieved ≥5% weight reduction following week 72 of tirzepatide (86%-100%) compared with placebo (18%-30%) across subgroups, and all subgroups showed improvements in cardiometabolic parameters with tirzepatide. Safety profiles did not substantially differ by subgroup. 2 2

CONCLUSIONS: These results suggest that tailored interventions such as tirzepatide dosage adjustments may help optimise the treatment management of Japanese patients with obesity disease.

STUDY REGISTRATION: ClinicalTrials.gov, NCT04844918.

Key numbers

-17.5%

Weight Reduction Female

Percent body weight reduction at week 72 for 10 mg.

-18.7%

Weight Reduction BMI <35 kg/m

Percent body weight reduction at week 72 for 10 mg.

86%–100%

Achievement of ≥5% Weight Reduction

Proportion of participants achieving at least 5% weight reduction at week 72.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief